AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B

AstraZeneca (AZN) announced a definitive agreement to acquire Fusion Pharmaceuticals (FUSN) , which will add next-generation radioconjugates, a promising modality in cancer treatment, to its cancer pipeline.AstraZeneca has offered to acquire Fusion, a Canadian company, for a price of $21.00 per share in cash, which represents a premium of 97% to the latter’s closing price of $10.64 on Monday, Mar 18. In addition, AstraZeneca will be entitled to make a non-transferable contingent value (CV) payment of $3.00 ...